Illumina’s (ILMN) “Overweight” Rating Reiterated at Stephens

Stephens reissued their overweight rating on shares of Illumina (NASDAQ:ILMN) in a research report report published on Tuesday,Benzinga reports. The firm currently has a $156.00 target price on the life sciences company’s stock.

Several other equities analysts also recently issued reports on ILMN. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $130.00 to $100.00 in a research report on Monday, February 10th. Guggenheim cut their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Finally, Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Stock Down 0.2 %

NASDAQ ILMN opened at $84.05 on Tuesday. Illumina has a twelve month low of $80.18 and a twelve month high of $156.66. The stock has a market cap of $13.31 billion, a PE ratio of -10.94, a PEG ratio of 1.60 and a beta of 1.17. The firm has a 50-day simple moving average of $114.52 and a 200 day simple moving average of $130.20. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts forecast that Illumina will post 4.51 EPS for the current year.

Institutional Trading of Illumina

Several hedge funds have recently modified their holdings of the stock. Bleakley Financial Group LLC bought a new position in Illumina during the fourth quarter worth $751,000. Zacks Investment Management acquired a new position in shares of Illumina during the third quarter valued at about $2,924,000. Van ECK Associates Corp boosted its position in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in shares of Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP increased its position in Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after buying an additional 6,263 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.